0001209191-19-018232.txt : 20190308 0001209191-19-018232.hdr.sgml : 20190308 20190308175115 ACCESSION NUMBER: 0001209191-19-018232 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190307 FILED AS OF DATE: 20190308 DATE AS OF CHANGE: 20190308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Currie Mark G CENTRAL INDEX KEY: 0001478244 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34620 FILM NUMBER: 19670276 MAIL ADDRESS: STREET 1: C/O IRONWOOD PHARMACEUTICALS INC STREET 2: 320 BENT STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001446847 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043404176 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-07 0 0001446847 IRONWOOD PHARMACEUTICALS INC IRWD 0001478244 Currie Mark G C/O IRONWOOD PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Scientific Officer Class A Common Stock 2019-03-07 4 S 0 225500 13.29 D 577980 D Class A Common Stock 2019-03-08 4 S 0 49500 13.15 D 528480 D Mark Currie sold the shares of common stock of Ironwood Pharmaceuticals, Inc. to raise proceeds to fund a portion of his commitment to purchase shares of common stock of Cyclerion Therapeutics, Inc. alongside other investors in a private placement. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.94 to $13.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.04 to $13.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Conor Kilroy, Attorney-in-Fact 2019-03-08